

NDC	DRUG_PROD_DESC	INTRODUCED_TO_MARKET_DATE	WAC_AT_INTRODUCTION	MARKETING_PRICING_PLAN	ESTIMATED_PATIENTS
0078070802	Piqray 300 mg /56 tablets (150mg tabs)	5/24/2019	15500	Novartis considered many factors in determining the price of Piqray. We consider the value the medicine brings to the patient population, the healthcare system, and society. We also consider the research and development costs, as well as ongoing costs for marketing, regulatory commitments, ongoing pharmacovigilance, and market conditions and dynamics. Piqray is the first and only treatment specifically for the approximately 40% of HR+/HER2- advanced breast cancer patients with a PIK3CA mutation, bringing a biomarker-driven therapy option to people with HR+/HER2- advanced breast cancer for the first time. Advanced breast cancer is incurable, and patients with all types need more treatment options. With this approval, physicians can now use an FDA-approved test to determine if their patients' HR+/HER2- advanced breast cancer has a PIK3CA mutation and may benefit from Piqray combination therapy. We are focused on access to Piqray for this patient population.	43,000
0078071502	Piqray 250 mg / 56 tablets (28 of the 200 mg tabs & 28 of the 50 mg tabs)	5/24/2019	15500	Novartis considered many factors in determining the price of Piqray. We consider the value the medicine brings to the patient population, the healthcare system, and society. We also consider the research and development costs, as well as ongoing costs for marketing, regulatory commitments, ongoing pharmacovigilance, and market conditions and dynamics. Piqray is the first and only treatment specifically for the approximately 40% of HR+/HER2- advanced breast cancer patients with a PIK3CA mutation, bringing a biomarker-driven therapy option to people with HR+/HER2- advanced breast cancer for the first time. Advanced breast cancer is incurable, and patients with all types need more treatment options. With this approval, physicians can now use an FDA-approved test to determine if their patients' HR+/HER2- advanced breast cancer has a PIK3CA mutation and may benefit from Piqray combination therapy. We are focused on access to Piqray for this patient population.	43,000
0078070184	Piqray 200 mg / 28 tablets (28 of the 200mg tabs)	5/24/2019	15500	Novartis considered many factors in determining the price of Piqray. We consider the value the medicine brings to the patient population, the healthcare system, and society. We also consider the research and development costs, as well as ongoing costs for marketing, regulatory commitments, ongoing pharmacovigilance, and market conditions and dynamics. Piqray is the first and only treatment specifically for the approximately 40% of HR+/HER2- advanced breast cancer patients with a PIK3CA mutation, bringing a biomarker-driven therapy option to people with HR+/HER2- advanced breast cancer for the first time. Advanced breast cancer is incurable, and patients with all types need more treatment options. With this approval, physicians can now use an FDA-approved test to determine if their patients' HR+/HER2- advanced breast cancer has a PIK3CA mutation and may benefit from Piqray combination therapy. We are focused on access to Piqray for this patient population.	43,000

NDC	DRUG_PROD_DESC	BREAKTHROUGH_THERAPY_INDICATOR	PRIORITY_REVIEW_INDICATOR	ACQUISITION_DATE	ACQUISITION_PRICE
0078070802	Piqray 300 mg /56 tablets (150mg tabs)	N/A	N/A	N/A	N/A
0078071502	Piqray 250 mg / 56 tablets (28 of the 200 mg tabs & 28 of the 50 mg tabs)	N/A	N/A	N/A	N/A
0078070184	Piqray 200 mg / 28 tablets (28 of the 200mg tabs)	N/A	N/A	N/A	N/A

NDC	DRUG_PROD_DESC	GENERAL_COMMENTS
0078070802	Piqray 300 mg /56 tablets (150mg tabs)	We believe that all information submitted by Novartis to the Department of Vermont Health Access or to the Attorney General under Vt. Stat. tit. 18 §§ 4635 or 4637, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis' related information herein be maintained to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) or otherwise, we request that Novartis be notified of the request and afford us the opportunity to submit objections to disclosure.
0078071502	Piqray 250 mg / 56 tablets (28 of the 200 mg tabs & 28 of the 50 mg tabs)	We believe that all information submitted by Novartis to the Department of Vermont Health Access or to the Attorney General under Vt. Stat. tit. 18 §§ 4635 or 4637, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis' related information herein be maintained to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) or otherwise, we request that Novartis be notified of the request and afford us the opportunity to submit objections to disclosure.
0078070184	Piqray 200 mg / 28 tablets (28 of the 200mg tabs)	We believe that all information submitted by Novartis to the Department of Vermont Health Access or to the Attorney General under Vt. Stat. tit. 18 §§ 4635 or 4637, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis' related information herein be maintained to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) or otherwise, we request that Novartis be notified of the request and afford us the opportunity to submit objections to disclosure.